Immunotech Biopharm Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	21.05	46.96	52.16	58.45	353.34	845.39
Trading Asset Securities	-	10.54	124.81	21.01	-	-
Cash & Short-Term Investments	21.05	57.49	176.97	79.46	353.34	845.39
Cash Growth	-85.51%	-67.51%	122.72%	-77.51%	-58.20%	199.52%
Other Receivables	-	0.1	-	-	-	-
Receivables	-	0.1	-	-	-	-
Inventory	5.42	5.54	4.92	7.21	10.87	3.98
Other Current Assets	14.29	24.36	32	31.44	47.99	34.36
Total Current Assets	40.76	87.49	213.89	118.11	412.2	883.72
Property, Plant & Equipment	424.46	451.6	500.76	527.25	426.59	154.49
Long-Term Investments	-	-	46.36	140.18	163.18	131.97
Other Intangible Assets	18.57	19.55	41.88	42.49	14.25	7.37
Long-Term Deferred Charges	0.13	0.21	0.46	0.72	0.98	1.23
Other Long-Term Assets	4.98	5.18	42.92	50.69	80.5	31.44
Total Assets	488.9	564.04	846.28	879.44	1,098	1,210
Accounts Payable	40.35	33.61	46.76	37.39	32.15	5.84
Accrued Expenses	17	21	21.65	27.17	22.24	5.76
Current Portion of Long-Term Debt	318.59	268.1	326.84	-	-	-
Current Portion of Leases	30.24	27.45	24.68	26.06	20.21	7.2
Current Income Taxes Payable	-	0.96	-	-	-	-
Current Unearned Revenue	1.47	1.78	1.85	4.36	5.19	4.25
Other Current Liabilities	88.89	77.31	108.5	113.49	100.31	8.57
Total Current Liabilities	496.54	430.21	530.28	208.47	180.1	31.62
Long-Term Debt	-	-	-	1	-	-
Long-Term Leases	81.5	89.02	105.66	122.75	90.85	43.86
Long-Term Unearned Revenue	56.35	61.27	39.46	40.84	3.56	5.91
Total Liabilities	634.38	580.5	675.39	373.07	274.51	81.38
Common Stock	3.58	3.58	3.58	3.58	3.58	3.58
Additional Paid-In Capital	1,402	1,402	1,402	1,402	1,402	1,402
Retained Earnings	-1,934	-1,805	-1,618	-1,283	-965.22	-610.99
Comprehensive Income & Other	385.69	385.69	385.69	385.69	381.4	332.46
Total Common Equity	-142.4	-13.3	173.62	508.44	822.26	1,128
Minority Interest	-3.09	-3.16	-2.73	-2.07	0.92	1.31
Shareholders' Equity	-145.49	-16.45	170.89	506.37	823.18	1,129
Total Liabilities & Equity	488.9	564.04	846.28	879.44	1,098	1,210
Total Debt	430.32	384.56	457.17	149.81	111.05	51.06
Net Cash (Debt)	-409.27	-327.07	-280.2	-70.35	242.29	794.33
Net Cash Growth	-	-	-	-	-69.50%	226.55%
Net Cash Per Share	-0.80	-0.64	-0.54	-0.14	0.47	1.79
Filing Date Shares Outstanding	514.58	514.58	514.58	514.58	514.58	514.58
Total Common Shares Outstanding	514.58	514.58	514.58	514.58	514.58	514.58
Working Capital	-455.78	-342.71	-316.38	-90.36	232.1	852.11
Book Value Per Share	-0.28	-0.03	0.34	0.99	1.60	2.19
Tangible Book Value	-160.97	-32.85	131.73	465.95	808.01	1,120
Tangible Book Value Per Share	-0.31	-0.06	0.26	0.91	1.57	2.18
Land	-	83.92	83.92	83.92	63.05	50.15
Machinery	-	153.36	149.53	86.1	76.5	41.34
Construction In Progress	-	113.42	107.65	208.53	151.85	2.5
Leasehold Improvements	-	121.83	121.83	56.69	56.25	28.99

Source: S&P Global Market Intelligence. Standard template. Financial Sources.